AI Therapeutics (now Orphai Therapeutics) is a clinical-stage biopharmaceutical company founded in Guilford, Connecticut by Jonathan Rothberg as LAM Therapeutics, renamed AI Therapeutics, and renamed again to OrphAI Therapeutics in September 2023. It built an internal deep-learning platform that synthesized public and proprietary drug and disease data to match existing chemical entities to new indications, and used it to advance a rare-disease and pulmonary pipeline — LAM-001, an inhaled formulation of sirolimus (rapamycin) targeting mTOR-driven pulmonary disease, plus the earlier PIKfyve inhibitor programs LAM-002 and LAM-003. Quince Therapeutics (Nasdaq: QNCX) acquired Orphai in May 2026 and now runs it as a subsidiary. The AI platform is an internal drug-discovery tool, not a product: the company operates no developer program, publishes no API, SDK or machine-readable contract, and its public web presence is a single-page corporate site.
AI Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: ai-therapeutics
name: AI Therapeutics
description: 'AI Therapeutics (now Orphai Therapeutics) is a clinical-stage biopharmaceutical company founded in Guilford,
Connecticut by Jonathan Rothberg as LAM Therapeutics, renamed AI Therapeutics, and renamed again to OrphAI Therapeutics
in September 2023. It built an internal deep-learning platform that synthesized public and proprietary drug and disease
data to match existing chemical entities to new indications, and used it to advance a rare-disease and pulmonary pipeline
— LAM-001, an inhaled formulation of sirolimus (rapamycin) targeting mTOR-driven pulmonary disease, plus the earlier PIKfyve
inhibitor programs LAM-002 and LAM-003. Quince Therapeutics (Nasdaq: QNCX) acquired Orphai in May 2026 and now runs it as
a subsidiary. The AI platform is an internal drug-discovery tool, not a product: the company operates no developer program,
publishes no API, SDK or machine-readable contract, and its public web presence is a single-page corporate site.'
url: https://raw.githubusercontent.com/api-evangelist/ai-therapeutics/refs/heads/main/apis.yml
image: https://orphai-therapeutics.com/wp-content/uploads/2026/07/orphai-logo-new.png
x-status: acquired
x-acquired-by: quince-therapeutics
x-acquired-date: '2026-05-18'
x-status-note: 'Renamed from LAM Therapeutics to AI Therapeutics, then to OrphAI Therapeutics in September 2023. Acquired
by Quince Therapeutics (Nasdaq: QNCX) on 2026-05-18 and now operated as a subsidiary; the live site orphai-therapeutics.com
carries the acquisition announcement and has been reduced to a single page.'
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-13'
modified: '2026-09-13'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Artificial Intelligence
- Clinical Trials
- Rare Disease
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://orphai-therapeutics.com/
- type: GitHubOrganization
url: https://github.com/AI-Therapeutics
- type: DomainSecurity
url: security/ai-therapeutics-domain-security.yml
x-enrichment:
date: '2026-09-13'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: AI Therapeutics is a clinical-stage biopharmaceutical company (now Orphai Therapeutics, a Quince Therapeutics subsidiary)
whose product is an inhaled rapamycin drug candidate, not software — its only live host, orphai-therapeutics.com, is a
one-page WordPress corporate site that 404s every /.well-known/, OpenAPI and llms.txt path, and its GitHub organization
has zero public repositories.
evidence:
- url: https://orphai-therapeutics.com/.well-known/agent-card.json
status: 404
- url: https://orphai-therapeutics.com/openapi.json
status: 404
- url: https://orphai-therapeutics.com/llms.txt
status: 404
- url: https://api.github.com/users/AI-Therapeutics/repos
status: 200
checked: '2026-09-13'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →